Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetyl-alpha-D-glucosaminidase is a lysosomal enzyme involved in the degradation of heparan sulfate, a glycosaminoglycan component of the extracellular matrix and cell surfaces. Deficiency or dysfunction of this enzyme leads to Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B, a rare autosomal recessive lysosomal storage disorder characterized by progressive neurodegeneration and accumulation of heparan sulfate in tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetyl-alpha-D-glucosaminidase.